Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective.

Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective. Br J Psychiatry. 2019 Apr 29;:1-2 Authors: López-Díaz Á, Murillo-Izquierdo M, Moreno-Mellado E Abstract SummaryKetamine therapy for treatment-resistant depression in European national health systems may only be considered after attempting all evidence-based antidepressant strategies outlined in clinical guidelines. This paper seeks to explain the ethical, regulatory and procedural framework for the off-label use of ketamine for treatment-resistant depression within a public healthcare system.Declaration of interestNone. PMID: 31030677 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31030677?dopt=Abstract

Source: The British Journal of Psychiatry for Mental Science - April 30, 2019 Category: Psychiatry Tags: Br J Psychiatry Source Type: research